~~<i id='D2CA5FB6A4'><strike id='D2CA5FB6A4'><tt id='D2CA5FB6A4'><pre id='D2CA5FB6A4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：comprehensive 2025-10-02 21:05:35 - browse：55996

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Illumina slashes 2023 revenue projections yet again

entertainment

focus

Wikipedia

focus

leisure time

TheprofitmarginatOptumHealthisatthelowestinadecade.CourtesyUnitedJustweeksafterthedivisionofUnitedHe

WSS

Patients' immediate access to test results puts radiologists in a bind

Illinois Supreme Court finds assault weapons ban constitutional

YouTube cracks down on misinformation on cancer treatment

What to know about the judge who will handle the Trump case

Congenital heart disease patients face new threat of heart failure

Illumina slashes 2023 revenue projections yet again

leisure time

entertainment

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Mark Cuban is blaming the wrong people for high drug costs

The high cost of giving birth even with insurance

AI models in health care face new federal disclosure requirements

Medical records are filled with copy

Surge in Apellis stock fueled by confidence in safety of its eye drug

As demand for Covid shots wanes, Moderna seeks its next success

After sickle

ChatGPT in medicine: STAT answers readers' burning questions

Pfizer plans to depart BIO

focus

Dozens dead from Maui wildfires: What we know about the victims

Novo Nordisk touts Wegovy study, but still struggling with supply

Biogen’s boardroom scandal saddles CEO with first crisis

Pharma patents targeted by Biden in move to slash drug prices

After sickle

Maui wildfire now ranks as the fifth

Wikipedia

focus

focus

leisure time